Polyrizon Ltd. ( (PLRZ) ) has shared an update.
On March 31, 2025, Polyrizon Ltd. announced a $17.0 million private placement agreement with institutional investors, involving the sale of Ordinary Units and Pre-Funded Units. The transaction, which closed on April 1, 2025, is expected to provide the company with significant capital for general corporate purposes and working capital. Aegis Capital Corp. acted as the exclusive placement agent for the offering. This strategic financial move positions Polyrizon to further its development of intranasal hydrogel technologies, potentially enhancing its market presence in the biotech industry.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotech company specializing in the development of innovative intranasal hydrogels. These hydrogels are designed to form a protective barrier in the nasal cavity, potentially acting as a ‘biological mask’ to shield against viruses and allergens. The company is further developing its Capture and Contain (C&C) hydrogel technology for enhanced bioadhesion and retention in the nasal cavity, as well as exploring its Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients.
YTD Price Performance: -79.84%
Average Trading Volume: 328,344
Technical Sentiment Signal: Strong Buy
See more data about PLRZ stock on TipRanks’ Stock Analysis page.